tiprankstipranks
Trending News
More News >
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market

Maze Therapeutics, Inc. (MAZE) Income Statement

Compare
58 Followers

Maze Therapeutics, Inc. Income Statement

Last quarter (Q3 2025), Maze Therapeutics, Inc.'s total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Maze Therapeutics, Inc.'s net income was $-30.09M. See Maze Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22
Total Revenue
$ 167.50M$ 0.00$ 0.00
Gross Profit
$ 167.50M$ 0.00$ 0.00
Operating Expenses
$ 109.91M$ 98.55M$ 111.03M
Depreciation and Amortization
$ 3.30M$ 4.09M$ 3.82M
EBITDA
$ 60.88M$ -94.46M$ -107.21M
Operating Income
$ 57.59M$ -98.55M$ -111.03M
Other Income/Expenses
$ -4.18M$ -1.86M$ -3.91M
Pretax Income
$ 53.40M$ -100.42M$ -114.94M
Net Income
$ 52.23M$ -100.42M$ -114.94M
Per Share Metrics
Basic EPS
$ 0.08$ -2.29$ -2.63
Diluted EPS
$ 0.08$ -2.29$ -2.63
Weighted Average Shares Outstanding
43.80M 43.78M 43.78M
Weighted Average Shares Outstanding (Diluted)
43.80M 43.78M 43.78M
Currency in USD

Maze Therapeutics, Inc. Earnings and Revenue History